By Alexander Maxwell : Having previously updated the investment community in part 3 of my Biotechnology Catalysts series, the purpose of this article is to help give investors an idea of the upcoming biotechnology catalysts through the end of September. It can be hard for investors to be able to ...
and controls patents and patent applications for XIAFLEX and is entitled to get royalties until 2028 from Auxilium (NASDAQ: AUXL ) for Dupuytren's Contracture, Peyronie's Disease, Frozen Shoulder and Cellulite. Thomas L. Wegman, President of BioSpecifics
By Andy Batts : Auxilium Pharmaceuticals (NASDAQ: AUXL ) recently reported its second quarter 2014 financial results ..... excellent investing opportunity for long-term investors. AUXL data by YCharts The decline in Auxilium's second quarter
By Uncommon Profit Investor : Tax inversion frenzy Tax inversion is the method of lowering a US company's tax rate by acquiring a foreign company. As long as the shareholders of the foreign company being acquired own at least 20% of the shares of the combined company, the acquirer can take on the
Auxilium Pharmaceuticals (NASDAQ: AUXL ) appoints Andrew Saik as CFO effective August 18, 2014. He joins the firm from Endo Health Solutions where he was SVP, Finance and Treasurer. Post your comment!
Auxilium Pharmaceuticals (NASDAQ: AUXL ) Q2 2014 Earnings Call August 07, 2014 8:30 am ET ..... Good day, ladies and gentlemen, and welcome to the Q2 Auxilium Pharmaceuticals Incorporated Earnings Conference Complete Story »
The following audio is from a conference call that will begin on August 07, 2014 at 08:30 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
Auxilium Pharmaceuticals ( AUXL +2.6% ) Q2 results : Revenues: $83.0M (-17.4%); Operating Expenses: $110.2M (-14.5%); Operating Loss
Aug 7 (Reuters) - Drugmaker Auxilium Pharmaceuticals posted a much bigger-than-expected quarterly loss, hurt by falling sales of testosterone gel Testim.
Auxilium Pharmaceuticals (NASDAQ: AUXL ): Q2 EPS of -$0.44 misses by $0.23 . Revenue of $83M (-17.4% Y/Y) misses by $5.52M . Press Release Post your comment!